Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q6PIW4

UPID:
FIGL1_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q6PIW4; D3DVM6; Q86V18; Q8ND59; Q9H8P1; Q9H917

BACKGROUND:
Fidgetin-like protein 1 is integral to the homologous recombination pathway for repairing DNA double-strand breaks, acting independently of BRCA2, RAD51, and their paralogs. Its recruitment at DNA damage sites is H2AX-dependent. Additionally, it may influence osteoblast proliferation and differentiation and is thought to contribute to the dynamics of male meiosis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Fidgetin-like protein 1 offers promising avenues for developing novel therapeutic approaches, especially in diseases marked by DNA repair defects. Its role in bone cell proliferation and differentiation also presents opportunities for targeting bone-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.